HC Wainwright Reiterates Neutral Rating for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN)‘s stock had its “neutral” rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports.

Agenus Stock Performance

NASDAQ AGEN opened at $3.83 on Wednesday. Agenus has a 52-week low of $2.50 and a 52-week high of $19.69. The company has a fifty day moving average of $3.12 and a 200-day moving average of $5.04. The company has a market capitalization of $89.85 million, a P/E ratio of -0.34 and a beta of 1.27.

Hedge Funds Weigh In On Agenus

A number of large investors have recently modified their holdings of AGEN. FMR LLC increased its holdings in shares of Agenus by 47.1% in the third quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock worth $467,000 after buying an additional 27,309 shares during the period. HighTower Advisors LLC grew its position in Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 7,530 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Agenus by 2,271.5% during the third quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 37,866 shares during the period. Geode Capital Management LLC grew its holdings in shares of Agenus by 7.1% in the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after purchasing an additional 32,016 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after buying an additional 9,731 shares during the period. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.